Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P220012/S071

Aurora EV ICD, Cobalt MRI ICD, Cobalt XT MRI ICD, Crome MRI ICD, Evera MRI DF-1 ICD, Evera MRI ICD

Medtronic, Inc. · Decision date Apr 28, 2026

FDA DECISIONP220012/S071

What did the FDA decide?

FDA records P220012/S071 as a supplement to PMA P220012, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 28, 2026.

FDA approval order statement

an alternate supplier for printed wiring board of the transformer component
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Apr 28, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P220012/S071
Regulatory pathway
PMA supplement
Product code
LWS
Decision code
OK30
Decision date
Apr 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implantable cardioverter defibrillator (non-CRT).

Product code
LWS
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P220012/S057 · Related supplement

    Aurora EV-ICD System (DVEA3E4)

  2. P220012/S058 · Related supplement

    Aurora EV ICD (DVEA3E4)

  3. P220012/S059 · Related supplement

    Aurora EV ICD (DVEA3E4)

  4. P220012/S062 · Related supplement

    Aurora EV ICD (DVEA3E4)

  5. P220012/S068 · Related supplement

    Aurora EV ICD; Epsila EV Extravascular Lead

  6. P220012/S071 received

    Application receipt date recorded by FDA.

  7. P220012/S070 · Related supplement

    Epsila EV Extravascular Lead

  8. P220012/S071 · FDA decision

    30-Day Notice

  9. P220012/S074 · Related supplement

    Aurora EV ICD (DVEA3E4)

  10. P220012/S075 · Related supplement

    Aurora EV-ICD (DVEA3E4)

Timeline entries are records held by MedtechLedger for P220012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P220012

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementJul 29, 2025FDA
Medtronic, Inc.PMA supplementAug 12, 2025FDA
Medtronic, Inc.PMA supplementSep 5, 2025FDA
Medtronic, Inc.PMA supplementSep 11, 2025FDA
Medtronic, Inc.PMA supplementOct 3, 2025FDA
Medtronic, Inc.PMA supplementOct 28, 2025FDA
Medtronic, Inc.PMA supplementDec 3, 2025FDA
Medtronic, Inc.PMA supplementDec 3, 2025FDA
Medtronic, Inc.PMA supplementDec 15, 2025FDA
Medtronic, Inc.PMA supplementJan 5, 2026FDA
Medtronic, Inc.PMA supplementJan 23, 2026FDA
Medtronic, Inc.PMA supplementFeb 10, 2026FDA
Aurora EV ICDP220012/S065
Medtronic, Inc.PMA supplementFeb 11, 2026FDA
Medtronic, Inc.PMA supplementFeb 12, 2026FDA
Medtronic, Inc.PMA supplementMar 6, 2026FDA
Medtronic, Inc.PMA supplementApr 15, 2026FDA
Aurora EV-ICDP220012/S072
Medtronic, Inc.PMA supplementApr 30, 2026FDA
Medtronic, Inc.PMA supplementJun 25, 2026FDA
Aurora EV ICDP220012/S073
Medtronic, Inc.PMA supplementJul 16, 2026FDA
Medtronic, Inc.PMA supplementJul 31, 2026FDA
Medtronic, Inc.PMA supplementJul 31, 2026FDA

Explore the linked device profile

Other records with product code LWS

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. NE, Mv Mv S11, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records